MYGN Competitors & Alternatives
Compare Myriad Genetics Inc with similar stocks in the same industry
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
MYGN
Main Stock$4.75
Tradestie Score
53
Market Cap
$719.23M
Revenue Growth
0.0%
Analyst Upside
+63.8%
Top Competitors
19 stocks in IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES| Company | Price | Market Cap | P/E | Score | Action |
|---|---|---|---|---|---|
|
IDXX
Idexx Laboratories Inc
|
$569.55
|
$49.61B | 43.1 | 60 | Compare |
|
LNTH
Lantheus Holdings, Inc
|
$76.10
|
$3.51B | 22.2 | 61 | Compare |
|
QDEL
QuidelOrtho Corporation Common Stock
|
$17.25
|
$2.12B | - | 51 | Compare |
|
NTLA
Intellia Therapeutics, Inc
|
$13.13
|
$2.01B | - | 53 | Compare |
|
CLDX
Celldex Therapeutics, Inc
|
$31.06
|
$1.68B | - | 57 | Compare |
|
NNNN
Anbio Biotechnology Class A Ordinary Shares
|
$25.85
|
$1.53B | 428.5 | 49 | Compare |
|
NEOG
Neogen Corp
|
$9.41
|
$1.26B | - | 56 | Compare |
|
TKNO
Alpha Teknova, Inc. Common Stock
|
$3.16
|
$340.89M | - | 60 | Compare |
|
ACHV
Achieve Life Sciences, Inc.
|
$3.23
|
$158.43M | - | 52 | Compare |
|
IMDX
Insight Molecular Diagnostics Inc. Common Stock
|
$3.76
|
$94.16M | - | 42 | Compare |
More MYGN Analysis
Data updated: Apr 05, 2026 | Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES (SIC 2835)
19 stocks in this industry